Fulop V, Mok S C, Genest D R, Gati I, Doszpod J, Berkowitz R S
Department of Obstetrics and Gynecology and Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
J Reprod Med. 1998 Feb;43(2):119-27.
To determine the expression of p53, p21, Rb and mdm2 proteins in normal placentas, partial and complete hydatidiform moles, and choriocarcinomas and to examine possible p53 mutations in specimens from p53-positive cases.
Expression of the above oncoproteins was determined immunohistochemically by specific antibodies for these proteins on formalin-fixed paraffin sections of 18 normal placentas, 17 partial moles, 25 complete moles and 11 choriocarcinomas. This was followed by polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis (exons 5, 6, 7, 8, 9, 10, 11) for possible p53 mutation in specimens from p53-positive cases of complete mole and choriocarcinoma.
p53 Oncoprotein immunoreactivity was significantly stronger in complete mole and choriocarcinoma than in normal placenta (P < .0001, P < .0001) and in partial mole (P < .0001, P < .0001). Positive staining for p21 oncoprotein was also significantly stronger in complete mole (P < .0001, P < .0001) and in choriocarcinoma (P < .0001, P < .0001) than in placenta and partial mole. We found significantly stronger staining for Rb protein in complete mole (P < .03) and choriocarcinoma (P < .03) than in partial mole. Partial mole and complete mole expressed significantly stronger staining of mdm2 than placenta (P < .007, P < .07, respectively). We found only one nonsense mutation in p53 with PCR analysis; that strongly suggests that in complete mole and choriocarcinoma the overexpressed p53 protein was wild type.
Altered expression of p53, p21, Rb and mdm2 may be important in the pathogenesis of both complete mole and choriocarcinoma. However, unlike complete molar pregnancy, partial mole is not characterized by overexpression of p53. Overexpression of p53 and mdm2 proteins in complete mole and choriocarcinoma may be associated with more aggressive behavior in gestational trophoblastic disease.
确定p53、p21、Rb和mdm2蛋白在正常胎盘、部分性和完全性葡萄胎以及绒毛膜癌中的表达,并检测p53阳性病例标本中可能存在的p53突变。
通过针对这些蛋白的特异性抗体,采用免疫组织化学方法,在18例正常胎盘、17例部分性葡萄胎、25例完全性葡萄胎和11例绒毛膜癌的福尔马林固定石蜡切片上,检测上述癌蛋白的表达。随后,对完全性葡萄胎和绒毛膜癌的p53阳性病例标本进行聚合酶链反应单链构象多态性(PCR-SSCP)分析(第5、6、7、8、9、10、11外显子),以检测可能的p53突变。
p53癌蛋白免疫反应性在完全性葡萄胎和绒毛膜癌中显著强于正常胎盘(P <.0001,P <.0001)和部分性葡萄胎(P <.0001,P <.0001)。p21癌蛋白的阳性染色在完全性葡萄胎(P <.0001,P <.0001)和绒毛膜癌(P <.0001,P <.0001)中也显著强于胎盘和部分性葡萄胎。我们发现完全性葡萄胎(P <.03)和绒毛膜癌(P <.03)中Rb蛋白的染色显著强于部分性葡萄胎。部分性葡萄胎和完全性葡萄胎中mdm2的染色显著强于胎盘(分别为P <.007,P <.07)。PCR分析仅发现1例p53无义突变;这强烈提示在完全性葡萄胎和绒毛膜癌中,过表达的p53蛋白为野生型。
p53、p21、Rb和mdm2表达的改变在完全性葡萄胎和绒毛膜癌的发病机制中可能具有重要意义。然而,与完全性葡萄胎妊娠不同,部分性葡萄胎的特征不是p53过表达。完全性葡萄胎和绒毛膜癌中p53和mdm2蛋白的过表达可能与妊娠滋养细胞疾病中更具侵袭性的行为有关。